Complete Genomics Inc.

Pharma supply chains still may feel some long-lasting impacts from the proposed BIOSECURE Act, even though the bill appears unlikely to be enacted this year or perhaps ever, although it probably is to

The pending US election brings much uncertainty for the biopharma industry, but one thing is certain: firms are still going to have to worry about the BIOSECURE Act even after the presidential contest

With the BIOSECURE Act’s legislative progress on pause until after the election, the Pink Sheet is offering a look back on the Capitol Hill progress to date and a look ahead to the potential impact if

As the BIOSECURE Act gets closer to reality, Scrip looks at a couple of products where it could create gaps for US pharma majors and opportunities for other contract development and manufacturing or